WHY CHINA / EVIDENCE & REAL EXAMPLES
China combines major specialist hospitals, high-volume clinical services and expanding access to medical innovations. For international patients, speed, cost and suitability depend on the individual institution and procedure.
01 / THE CONSIDERATIONS
The choice to travel for healthcare should be based on medical suitability first. These are practical factors that make China a destination worth researching, not blanket claims that every service is faster, cheaper or better.
Large university-affiliated hospitals, dedicated specialty centres and advanced imaging, radiotherapy and surgical systems support complex specialist care in selected fields.
Some institutions offer concentrated testing and relatively fast hospital journeys. A reported Shanghai visitor received an X-ray result within roughly an hour. That is an individual account, not a guaranteed waiting time.
Read reported experience ↗For some specialist care, hospital-reported international comparisons indicate a possible cost advantage. Published comparisons may differ in scope, insurance and follow-up, so personalised written quotes matter more than headline percentages.
Example: CAR-T care pathway ↗02 / PUBLICLY DOCUMENTED HEALTHCARE EXAMPLES
These documented clinical or technology examples help illustrate the depth and variety of care in China. They are independent public reports, not INHE case studies, partner endorsements, treatment recommendations or guaranteed services.
The Shanghai Proton and Heavy Ion Center is a dedicated particle-radiotherapy facility. The Shanghai government reported 1,267 discharged patients in 2025 after particle therapy, reflecting an established specialist clinical program.
Specialist particle treatment · operating centre
Suitability depends on the cancer type, stage, prior treatment and specialist review.
Shanghai Government · Jan 2026 ↗A publicly reported international case at Ruijin Hospital involved a South African patient with multiple myeloma undergoing extensive testing before beginning a CAR-T-based treatment plan. This shows the level of specialist evaluation involved in complex cellular therapies.
Publicly reported international patient experience
Not all cancers or patients qualify for CAR-T treatment. This is not an INHE client case.
Shanghai Government · Feb 2026 ↗In 2024, doctors in Shanghai performed a reported remote lung-cancer procedure for a patient in Kashgar, approximately 5,000 kilometres away, using a domestically developed 5G surgical robot. It is an example of technological capability, not a routine service for medical visitors.
Documented remote surgery innovation
Robotic or remote surgery is not necessarily superior for every procedure or patient.
Shanghai Government · Jul 2024 ↗A 2026 report described a Russian university professor who received boron neutron capture therapy (BNCT) in Boao Lecheng. The report illustrates a specialist, technology-intensive care pathway for selected cancer cases.
Documented international visitor · May 2026
BNCT is highly specialised; current provider capability, indication and clinical eligibility require direct verification.
Hainan Government · Jun 2026 ↗Hainan government reporting describes access through Lecheng to vamorolone, a medicine for Duchenne muscular dystrophy, first introduced locally under a special pathway in April 2024. The example is about regulated medicine access, not a universal treatment entitlement.
Condition-specific medicine access
Availability depends on approval status, prescribing requirements, patient assessment and institution.
Hainan Government · Apr 2026 ↗Hainan reported that ruxolitinib cream (Opzelura), an internationally approved vitiligo treatment, was introduced through Lecheng; by November 2025, nearly 8,000 patients had reportedly accessed it within the pilot zone.
Institution-specific innovative medicine pathway
Prescription, indication and access depend on current regulations and medical assessment.
Hainan Government · Jan 2026 ↗Zhongshan Hospital, affiliated with Fudan University, presented an AI-assisted endoscopy system integrating imaging, procedural support and report drafting in 2025. The development demonstrates research capability, not a promise that a specific AI system is offered to visitors.
Technology development · clinical implementation varies
Verify whether the technology is in research, pilot or standard clinical use before making arrangements.
Shanghai Government · Apr 2025 ↗In March 2026, China's National Medical Products Administration approved an implantable brain–computer interface system designed to assist hand-grasp function in selected adults living with quadriplegia from cervical spinal cord injury. The device uses brain-signal decoding and an assisting pneumatic glove.
Regulatory approval · specific rehabilitation indication
Approval does not mean general availability to foreign visitors or suitability for other neurological conditions. Provider access and eligibility must be confirmed.
National Medical Products Administration · Mar 2026 ↗Clinical reality: Some examples describe established services, some special-access medicines, and others emerging or research-stage technology. These categories are not interchangeable.
Institutional credentials, current availability, medical eligibility, risks, waiting times and patient charges must be evaluated independently for each case.
03 / SPEED, COST & PRACTICAL REALITY
High-end healthcare should be compared on total value, not a single headline price.
Some Chinese centres report competitive prices and shorter timeframes for selected medical pathways. A Shanghai private hospital, for example, described an integrated 23-day CAR-T program and a substantially lower provider-estimated cost than certain Western comparisons. This is the hospital's own statement, not an independent universal price benchmark.
Travel expenses, pre-treatment tests, possible complications, interpreting, lodging, follow-up needs and insurance coverage can change the total. Clinical appropriateness comes first.
Read the provider-reported comparison ↗04 / WHERE INHE HELPS
Our job is to make the practical route clearer.
We start with your non-sensitive brief, research potentially relevant institutions, clarify international patient enquiry routes, organise non-clinical arrangements and help communicate across languages and stakeholders.
We do not decide which treatment you should receive. Medical examinations, treatment decisions, eligibility and clinical follow-up belong to the receiving licensed professionals.
Explore Guangzhou & Hainan ↗